… that SHP2 inhibition is synthetic lethal with MEK inhibition in … inhibition may further enhance
the effect of SHP2 inhibition. … inhibition of SHP2 could have clinical utility for KRAS-mutant …

… We also found that combining SHP2 and MEK inhibitors led to enhanced antiproliferative
activity and MAPK pathway suppression in KRAS-mutant cells with RTK/SHP2–mediated …

… that inhibition of SHP2 or RTKs is effective at treating a variety of KRAS mutant cancers that
are … on upstream growth factor signaling, including some KRAS G13D and Q61H mutants. …

… harboring KRAS/LKB1 comutation, which occurs in 30% of KRASmutant NSCLC, have a
significantly lower response rate to IOs compared to those with KRAS mutations alone or KRAS/…

… Finally, we revealed that SHP2 inhibitor increased the sensitivity of TKIs … inhibition. Our
results suggest a possibility of using a combination of SHP2 inhibitor and TKIs for KRAS-mutant …

… Although KRAS mutations are virtually universal in pancreatic ductal adenocarcinoma (…
rationale for a dual SHP2/MEK inhibition, we targeted SHP2 in co-inhibition assays with two …

… To more directly interrogate the effects of SHP2 inhibition on other KRAS mutants, we
used RAS-less mouse embryonic fibroblasts (MEF; ref. 19). As in MIAPaCa-2 cells, …

… In the present study, PCC0208023 was synthesized to investigated its inhibitory effects
against SHP2 enzyme, the KRAS-mutant CRC in vitro and in vivo, and the RAS/MAPK signaling …

… resistance associated with Q61H, we first compared the nucleotide-exchange properties of
six oncogenic KRAS mutants, as one of the established functions of SHP2 is to promote the …

… , events that were almost exclusive to gastroesophageal tumors, with exome sequencing
demonstrating that the majority of these tumors lack detectable KRAS mutations 3,4 . …